Lazard Asset Management’s Cellebrite CLBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.13M Buy
+154,863
New +$2.33M ﹤0.01% 867
2025
Q4
Sell
-508,538
Closed -$9.42M 1914
2025
Q3
$9.42M Buy
508,538
+72,869
+17% +$1.14M 0.01% 438
2025
Q2
$6.97M Sell
435,669
-46,968
-10% -$837K 0.01% 642
2025
Q1
$9.38M Buy
482,637
+285,149
+144% +$6M 0.01% 504
2024
Q4
$4.35M Buy
197,488
+7,058
+4% +$136K 0.01% 673
2024
Q3
$3.21M Sell
190,430
-113,526
-37% -$1.68M ﹤0.01% 746
2024
Q2
$3.63M Buy
303,956
+282,259
+1,301% +$3.15M ﹤0.01% 749
2024
Q1
$240K Buy
21,697
+4,842
+29% +$49.4K ﹤0.01% 1242
2023
Q4
$145K Sell
16,855
-13,798
-45% -$107K ﹤0.01% 1508
2023
Q3
$234K Buy
30,653
+3,005
+11% +$22.6K ﹤0.01% 1338
2023
Q2
$199K Buy
27,648
+13,405
+94% +$78.2K ﹤0.01% 1347
2023
Q1
$86K Buy
14,243
+6,749
+90% +$36.6K ﹤0.01% 1589
2022
Q4
$32K Buy
+7,494
New +$33.5K ﹤0.01% 1986

Other funds holding CLBT

Lazard Asset Management's CLBT Position: Q1 2026 in Review

Lazard Asset Management opened a new position in Cellebrite (CLBT) in Q1 2026: 154,863 shares worth $2.13M. The stake represents ﹤0.01% of the portfolio and ranks #867 among its holdings. This is a return to the name: Lazard Asset Management previously reported a position in CLBT as recently as Q3 2025.

Lazard Asset Management first reported a position in CLBT in Q4 2022 and has held it in 13 quarters since. The position peaked at $9.42M in Q3 2025. 220 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

  • Lazard Asset Management held 154,863 shares of Cellebrite worth $2.13M as of Q1 2026.
  • Cellebrite was a new Lazard Asset Management position in Q1 2026.
  • Cellebrite made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #867 holding.
  • Lazard Asset Management first reported a position in Cellebrite in Q4 2022 and has held it in 13 quarters since.
  • Lazard Asset Management's Cellebrite position peaked at $9.42M in Q3 2025.
  • 220 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.